Improved CRISPR-Cpf1 genome editing tool

J. van der Oost; P. van Baarlen; Rogier Louwen

Improved CRISPR-Cpf1 genome editing tool

J. van der Oost (Inventor), P. van Baarlen (Inventor), Rogier Louwen (Inventor)

Research output: Patent

Abstract

The invention relates to a Cpf1-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cpf1 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

Original language	English
Patent number	WO2017155407
Priority date	11/03/16
Publication status	Published - 14 Sep 2017

Access to Document

https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2017155407A1&KC=A1&FT=D&ND=3&date=20170914&DB=EPODOC&locale=en_EP

Cite this

@misc{5c6e74fa788a41718474d15812c72435,

title = "Improved CRISPR-Cpf1 genome editing tool ",

abstract = "The invention relates to a Cpf1-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cpf1 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.",

author = "{van der Oost}, J. and {van Baarlen}, P. and Rogier Louwen",

year = "2017",

month = sep,

day = "14",

language = "English",

type = "Patent",

note = "WO2017155407",

}

TY - PAT

T1 - Improved CRISPR-Cpf1 genome editing tool

AU - van der Oost, J.

AU - van Baarlen, P.

AU - Louwen, Rogier

PY - 2017/9/14

Y1 - 2017/9/14

N2 - The invention relates to a Cpf1-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cpf1 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

AB - The invention relates to a Cpf1-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cpf1 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

M3 - Patent

M1 - WO2017155407

ER -

Improved CRISPR-Cpf1 genome editing tool

Abstract

Access to Document

Fingerprint

Cite this